We came across a bullish thesis on MoonLake Immunotherapeutics on Valueinvestorsclub.com by skimmer610. In this article, we will summarize the bulls’ thesis on MLTX. MoonLake Immunotherapeutics's share was trading at $51.89 as of August 7th.
[caption id="attachment_575379" align="aligncenter" width="750"]MoonLake Immunotherapeutics (MLTX) represents a high-upside, asymmetric biotech opportunity ahead of its critical September 2025 Phase 3 readout (VELA) in hidradenitis suppurativa (HS). The company’s lead asset, sonelokimab—a...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.